More on BLSM
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.80 |
|
|||
| Open | $16.00 | ||||
| 52 Wk High | $1.85 | ||||
| 52 Wk Low | $0.80 | ||||
| Day High | $16.50 | ||||
| Day Low | $15.75 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 111,393 | ||||
- Form SCHEDULE 13D BlossomHill Therapeutics Filed by: ORBIMED ADVISORS LLC
- FDA grants fast track status to BlossomHill's lung cancer drug BH-30643
- BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
- Form SCHEDULE 13G BlossomHill Therapeutics Filed by: Vivo Innovation Fund II Holdings, L.P.
- Form SCHEDULE 13G BlossomHill Therapeutics Filed by: PERCEPTIVE ADVISORS LLC
- Form SCHEDULE 13D BlossomHill Therapeutics Filed by: Cormorant Asset Management, LP
- Form 4 BlossomHill Therapeutics For: Aug 10 Filed by: GORDON CARL L
- Form 4 BlossomHill Therapeutics For: Aug 10 Filed by: ORBIMED ADVISORS LLC
- Form 4 BlossomHill Therapeutics For: Aug 10 Filed by: Schmid John P.
- Form 4 BlossomHill Therapeutics For: Aug 06 Filed by: GORDON CARL L
Entities mentioned with BLSM
- IPO | View Related Stories »
- FDA | View Related Stories »
- JPMorgan | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Guggenheim | View Related Stories »
- OrbiMed Advisors | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
